It is reasonable to postulate that nonimmune cells that express CCR5 may migrate in response to a concentration gradient of CCL5, and thus investigation of CCR5 blockers as breast cancer therapeutic agents is in its early stages, and is bolstered by data from animal models of tumor progression showing promise as anti-metastasis agents (12). The gene discussed is CCL5; the disease is breast carcinoma.